HQY vs. CYTK, EXEL, JAZZ, GMED, ENSG, ELAN, PCVX, INSP, MASI, and TNET
Should you be buying HealthEquity stock or one of its competitors? The main competitors of HealthEquity include Cytokinetics (CYTK), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Globus Medical (GMED), The Ensign Group (ENSG), Elanco Animal Health (ELAN), Vaxcyte (PCVX), Inspire Medical Systems (INSP), Masimo (MASI), and TriNet Group (TNET).
Cytokinetics (NASDAQ:CYTK) and HealthEquity (NASDAQ:HQY) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, community ranking, earnings, analyst recommendations and dividends.
Cytokinetics has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
99.6% of HealthEquity shares are owned by institutional investors. 3.4% of Cytokinetics shares are owned by insiders. Comparatively, 2.7% of HealthEquity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Cytokinetics currently has a consensus price target of $79.33, suggesting a potential upside of 21.42%. HealthEquity has a consensus price target of $96.17, suggesting a potential upside of 19.82%. Given HealthEquity's higher probable upside, analysts plainly believe Cytokinetics is more favorable than HealthEquity.
In the previous week, Cytokinetics had 8 more articles in the media than HealthEquity. MarketBeat recorded 10 mentions for Cytokinetics and 2 mentions for HealthEquity. Cytokinetics' average media sentiment score of 1.06 beat HealthEquity's score of 0.44 indicating that HealthEquity is being referred to more favorably in the news media.
Cytokinetics received 259 more outperform votes than HealthEquity when rated by MarketBeat users. Likewise, 79.14% of users gave Cytokinetics an outperform vote while only 69.24% of users gave HealthEquity an outperform vote.
HealthEquity has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.
HealthEquity has a net margin of 5.57% compared to HealthEquity's net margin of -6,988.63%. Cytokinetics' return on equity of 6.91% beat HealthEquity's return on equity.
Summary
HealthEquity beats Cytokinetics on 10 of the 18 factors compared between the two stocks.
Get HealthEquity News Delivered to You Automatically
Sign up to receive the latest news and ratings for HQY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HQY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HealthEquity Competitors List
Related Companies and Tools
